Precigen. has been granted a patent for polynucleotides that encode cell tags aimed at enhancing immunotherapeutic applications. The invention includes methods and systems for regulating genetically engineered cell activity, featuring a recombinant polypeptide with specific amino acid sequence identity criteria. GlobalData’s report on Precigen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Precigen, Cancer treatment biomarkers was a key innovation area identified from patents. Precigen's grant share as of July 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Polynucleotides encoding cell tags for immunotherapy applications
The granted patent US12060585B2 outlines a series of claims related to recombinant polypeptides characterized by their amino acid sequences. The primary claim (Claim 1) specifies that the polypeptides must exhibit at least 90% identity with the sequences of SEQ ID NOs: 57, 73, 77, or 81, while explicitly excluding any intracellular signaling domains. Subsequent claims refine this definition, allowing for higher identity thresholds of 95% and 99% with SEQ ID NO: 57, as well as the inclusion of signal peptides. Claims 5 through 11 detail various signal peptides that can be incorporated, including specific sequences and those with at least 95% or 99% identity to designated SEQ ID NOs.
The patent further expands on the identity requirements for polypeptides related to SEQ ID NOs: 73, 77, and 81, with claims 12 to 15 allowing for similar identity percentages of 90%, 95%, and 99%. This structured approach to defining the recombinant polypeptides emphasizes the importance of sequence identity in their composition, which may have implications for their functional applications in biotechnology or therapeutic contexts. The claims collectively highlight the versatility of the polypeptides while maintaining specific criteria for their structural characteristics.
To know more about GlobalData’s detailed insights on Precigen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
